Cognition in the Study of Tamoxifen and Raloxifene
(Co-STAR Trial)
Recruiting in Palo Alto (17 mi)
+133 other locations
Overseen bySally A. Shumaker, PhD
Age: 65+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Wake Forest University
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
Eligibility Criteria
Inclusion Criteria
Women enrolled in STAR trial at a site participating in Co-STAR
65 years of age or older
Have been randomized into STAR but have not started taking the study drug OR enrolled in STAR for a minimum of one year
See 3 more
Treatment Details
Interventions
- Raloxifene (Selective Estrogen Receptor Modulator)
- Tamoxifen (Selective Estrogen Receptor Modulator)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Star participants assigned to TamoxifenExperimental Treatment1 Intervention
Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
Group II: Star participants assigned to RaloxifeneExperimental Treatment1 Intervention
Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Duke University Medical CenterDurham, NC
Wake Forest University School of MedicineWinston-Salem, NC
York Cancer CenterYork, PA
Thompson Cancer Survival CenterKnoxville, TN
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Wake Forest UniversityLead Sponsor
National Institute on Aging (NIA)Collaborator